A meta-analysis by Zhang et al[26] indicated that exon 19 deletion might be associated with longer PFS compared with EGFR exon 21 mutation after administration of first-line EGFR-TKIs for NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.